Pharma Mar (OTCMKTS:PHMMF) Shares Gap Up – Should You Buy?
by Michael Walen · The Markets DailyPharma Mar (OTCMKTS:PHMMF – Get Free Report) shares gapped up before the market opened on Tuesday . The stock had previously closed at $88.72, but opened at $96.00. Pharma Mar shares last traded at $96.00, with a volume of 5,500 shares trading hands.
Pharma Mar Price Performance
The business’s 50-day simple moving average is $90.15 and its 200-day simple moving average is $91.19. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.84 and a quick ratio of 2.25.
About Pharma Mar
PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.
The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.